Covid-Secure Borders

Debate between Jim McMahon and Nadhim Zahawi

Tuesday 15th June 2021 Commons Chamber

[The Minister for Covid Vaccine Deployment (Nadhim Zahawi)]

I welcome today’s debate on a matter that is, rightly, of significant public interest. It is slightly disappointing to hear the right hon. Member for Torfaen (Nick Thomas-Symonds) being found out by my hon. Friend the Member for East Surrey (Claire Coutinho) for really not understanding how viruses spread. If we are going to live with this virus, there will be variants. He has been asked over and over again, “What would you do?”, and unfortunately he has been found failing. Throughout the pandemic this Government have taken all the steps necessary to protect the public and help prevent the spread of the virus.

[Jim McMahon (Oldham West and Royton) (Lab/Co-op)]

Absolute nonsense.

[Nadhim Zahawi]

Well, we shall see. As of today, 30 million-plus people have had two doses. We are at 72 million doses in the United Kingdom, and we aim in the next four weeks to offer the double dose to two thirds of all adults. That is delivery, my friend.

Sometimes taking all the steps necessary means making difficult decisions—not that the Labour party understands these things—such as the Prime Minister’s announcement yesterday of the decision, informed by the data, to pause the move to step 4 of the road map. We are clear that the public expect a clear message that these decisions are based on the science. Public health has always been our No. 1 priority and we will not risk throwing away our hard-won achievements through the vaccination programme that have only been possible through the work of the British people.

Being led by the data and the science has also informed our approach at the border. The Government have put in place some of the most stringent covid border measures in the world. Each of the measures that we have put in place—informed by the latest scientific advice—adds layers of protection against importing the virus, including through reducing the risk of importing new variants.